London, February 15
February 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following changes to Board committee membership, effective immediately:
|Dominic Blakemore||Remuneration Committee||N/A|
|Olivier Bohuon||Nomination & Governance Committee||Science & Technology Committee|
|Ian Clark||Remuneration Committee; |
Science & Technology Committee
|Sara Mathew||Nomination & Governance Committee||Remuneration Committee|
Senior Assistant Company Secretary
For further information please contact:
|Ian Karpfirstname.lastname@example.org||+1 781 482 9018|
|Robert Coatesemail@example.com||+44 1256 894874|
|Lisa Adlerfirstname.lastname@example.org||+1 617 588 8607|
|Debbi Fordemail@example.com||+1 617 949 9083|
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.